Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety of Etoposide, Cytarabine, and PEG-rhG-CSF Combination Therapy vs. Disease-Specific Chemotherapy for Hematopoietic Stem Cell Mobilization in Lymphoma

NCT06520163 is registered in ClinicalTrials.gov with The Affiliated People's Hospital of Ningbo University as lead sponsor.

NCT NCT06520163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06520163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety of Etoposide, Cytarabine, and PEG-rhG-CSF Combination Therapy vs. Disease-Specific Chemotherapy for Hematopoietic Stem Cell Mobilization in Lymphoma
Lead sponsor
The Affiliated People's Hospital of Ningbo University
Phase
Phase 3
Overall status
Recruiting
Start date
August 1, 2024
Completion date
August 31, 2026
Enrollment
99 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic stem cell mobilization, non-hodgkin's lymphoma